Article Text

PDF
Original article
Diagnostic and prognostic impact of copeptin and high-sensitivity cardiac troponin T in patients with pre-existing coronary artery disease and suspected acute myocardial infarction
  1. Mihael Potocki1,
  2. Tobias Reichlin1,2,
  3. Simone Thalmann1,
  4. Christa Zellweger1,3,
  5. Raphael Twerenbold1,3,
  6. Miriam Reiter1,3,
  7. Stephan Steuer4,
  8. Stefano Bassetti5,
  9. Beatrice Drexler1,3,
  10. Claudia Stelzig1,3,
  11. Michael Freese1,3,
  12. Katrin Winkler6,7,
  13. Philip Haaf1,3,
  14. Cathrin Balmelli1,3,
  15. Willibald Hochholzer3,
  16. Stefan Osswald1,
  17. Christian Mueller1,3
  1. 1Department of Cardiology, University Hospital Basel, Basel, Switzerland
  2. 2Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
  3. 3Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
  4. 4Emergency department, Limmattalspital Zürich, Zürich, Switzerland
  5. 5Department of Internal Medicine, Kantonsspital Olten, Olten, Switzerland
  6. 6Servicio de Pneumologia, Hospital del Mar - IMIM, UPF, CIBERES, ISC III, Barcelona, Spain
  7. 7Servicio de Urgencias, Hospital del Mar - IMIM, Barcelona, Spain
  1. Correspondence to Professor Dr Christian Mueller, Department of Cardiology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland; muellerch{at}uhbs.ch

Abstract

Objective The early diagnosis of acute myocardial infarction (AMI) can be particularly challenging in patients with known coronary artery disease (CAD) due to pre-existing ECG changes and chronic increases in cardiac troponin (cTn) levels.

Design Of 1170 consecutive patients presenting with symptoms suggestive of AMI, 433 (37%) with pre-existing CAD were analysed in a prospective multicentre study and the diagnostic and prognostic impact of copeptin in combination with either fourth generation cardiac troponin T (cTnT) or high-sensitivity cTnT (hs-cTnT) was evaluated.

Results AMI was the final diagnosis in 78 patients with pre-existing CAD (18%). Copeptin was significantly higher in patients with AMI than in those without (26 pmol/l (IQR 9–71) vs 7 pmol/l (IQR 4–16), p<0.001). The diagnostic accuracy for AMI as quantified by the area under the receiver operating characteristic curve (AUC) was significantly higher for the combination of copeptin and cTnT than for cTnT alone (0.94 vs 0.86, p<0.001). The combination of copeptin and hs-cTnT (0.94) was trending to superiority compared with hs-cTnT alone (0.92, p=0.11). The combination of copeptin and the cTn assays was able to improve the negative predictive value up to 99.5% to rule out AMI. Copeptin was a strong and independent predictor of 1-year mortality (HR 4.18–4.63). Irrespective of cTn levels, patients with low levels of copeptin had an excellent prognosis compared with patients with raised levels of both copeptin and cTn (360-day mortality 2.8–3.6% vs 23.1–33.8%, p<0.001).

Conclusion In patients with pre-existing CAD, copeptin significantly improves the diagnostic accuracy if used in addition to cTnT, but only trended to superiority compared with hs-cTnT alone. Copeptin provides independent prognostic information, largely by overcoming the challenging interpretation of mild increases in hs-cTnT.

Clinical trial registration number ClinicalTrials Gov number NCT00470587.

  • Diagnosis
  • prognosis
  • acute myocardial infarction
  • sensitive troponin
  • copeptin
  • coronary artery disease
  • myocardial ischaemia and infarction (IHD)
  • acute coronary syndrome
  • syncope
  • risk stratification
  • heart failure
  • hypertension
  • arrhythmias
  • atrial fibrillation
  • atrioventricular block
  • defibrillation
  • radiofrequency ablation (RFA)

Statistics from Altmetric.com

Footnotes

  • Funding This work was supported by research grants from the Swiss National Science Foundation (PP00B-102853), the Swiss Heart Foundation, the University Basel, Abbott, Roche, Nanosphere, Siemens and the Department of Internal Medicine, University Hospital Basel.

  • Competing interests CM has received speaker honoraria from Abbott, ALERE, BRAHMS, Roche and Siemens. MP has received speaker honoraria from Abbott, BRAHMS and Roche. RT has received speaker honoraria from BRAHMS. The assays were donated by the manufacturers who had no role in the design of the study, analysis of the data, preparation of the manuscript or the decision to submit for publication.

  • Patient consent Written informed consent approved by the local ethics committees was obtained from all patients.

  • Ethics approval The study was carried out according to the principles of the Declaration of Helsinki and approved by the local ethics committees.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.